Helen Victoria Worthington

Helen Victoria Worthington

Top Cited Scholar 2024
Auto-generated profile, based on publicly available information

Helen Victoria Worthington

School of Dentistry, University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2002 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
DEDiana R Elbourne
Diana R Elbourne
DADouglas G Altman
Douglas G Altman
JHJulian Pt Higgins
Julian Pt Higgins
FCFrancois Curtin
Francois Curtin
HWHelen V Worthington
Helen V Worthington
AVAndy Vail
Andy Vail
Background Meta-analysis of randomized controlled trials (RCTs) is usually based on trials where patients are randomized individually into two different, parallel, treatment groups. This paper concentrates on RCTs of a different design—two-period, two-treatment cross-over trials. Methods The characteristics of these trials are outlined, with detailed examples of methods for analysis for both continuous and binary data. These case studies are then extended into the context of a meta-analysis. The Cochrane Library was surveyed to assess current practice for synthesis. Results Methods are described for continuous and binary data for use both when the necessary paired data are given and also when they need to be calculated or imputed, and some suggestions are provided to help people wishing to synthesize data from cross-over trials into meta-analyses. The survey suggested that about 8% of the trials in the Cochrane library were cross-over trials and 18% of the reviews referred to such trials, although there was no consistent approach to their inclusion into the reviews. Conclusions Methods do exist for including valuable information from two-period, two-treatment cross-over trials into quantitative reviews. However, poor reporting of cross-over trials will often impede attempts to perform a meta-analysis using the available methods.

24 March 2006 in BMJ
Verified
Journal Article
Closed access
PDF file
LHLee Hooper
Lee Hooper
RTRachel L Thompson
Rachel L Thompson
RHRoger Harrison
Roger Harrison
CSCarolyn D Summerbell
Carolyn D Summerbell
ANAndy R Ness
Andy R Ness
GSGeorge Davey Smith
George Davey Smith
Objective To review systematically the evidence for an effect of long chain and shorter chain omega 3 fatty acids on total mortality, cardiovascular events, and cancer. Data sources Electronic databases searched to February 2002; authors contacted and bibliographies of randomised controlled trials (RCTs) checked to locate studies. Review methods Review of RCTs of omega 3 intake for 3 6 months in adults (with or without risk factors for cardiovascular disease) with data on a relevant outcome. Cohort studies that estimated omega 3 intake and related this to clinical outcome during at least 6 months were also included. Application of inclusion criteria, data extraction, and quality assessments were performed independently in duplicate. Results Of 15 159 titles and abstracts assessed, 48 RCTs (36 913 participants) and 41 cohort studies were analysed. The trial results were inconsistent. The pooled estimate showed no strong evidence of reduced risk of total mortality (relative risk 0.87, 95% confidence interval 0.73 to 1.03) or combined cardiovascular events (0.95, 0.82 to 1.12) in participants taking additional omega 3 fats. The few studies at low risk of bias were more consistent, but they showed no effect of omega 3 on total mortality (0.98, 0.70 to 1.36) or cardiovascular events (1.09, 0.87 to 1.37). When data from the subgroup of studies of long chain omega 3 fats were analysed separately, total mortality (0.86, 0.70 to 1.04; 138 events) and cardiovascular events (0.93, 0.79 to 1.11) were not clearly reduced. Neither RCTs nor cohort studies suggested increased risk of cancer with a higher intake of omega 3 (trials: 1.07, 0.88 to 1.30; cohort studies: 1.02, 0.87 to 1.19), but clinically important harm could not be excluded. Conclusion Long chain and shorter chain omega 3 fats do not have a clear effect on total mortality, combined cardiovascular events, or cancer.

4 March 2019 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
TWTanya Walsh
Tanya Walsh
HWHelen V Worthington
Helen V Worthington
AGAnne-Marie Glenny
Anne-Marie Glenny
VMValeria Cc Marinho
Valeria Cc Marinho
AJAna Jeroncic
Ana Jeroncic

11 July 2013 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
VMValeria C C Marinho
Valeria C C Marinho
HWHelen V Worthington
Helen V Worthington
TWTanya Walsh
Tanya Walsh
JCJan E Clarkson
Jan E Clarkson
Background Topically‐applied fluoride varnishes have been used extensively as an operator‐applied caries‐preventive intervention for over three decades. This review updates the first Cochrane review of fluoride varnishes for preventing dental caries in children and adolescents, which was first published in 2002. Objectives To determine the effectiveness and safety of fluoride varnishes in preventing dental caries in children and adolescents, and to examine factors potentially modifying their effect. Search methods We searched the Cochrane Oral Health Group's Trials Register (to 13 May 2013), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2013, Issue 4), MEDLINE via OVID (1946 to 13 May 2013), EMBASE via OVID (1980 to 13 May 2013), CINAHL via EBSCO (1980 to 13 May 2013), LILACS and BBO via the BIREME Virtual Health Library (1980 to 13 May 2013), ProQuest Dissertations and Theses (1861 to 13 May 2013), and Web of Science Conference Proceedings (1945 to 13 May 2013). A search for ongoing trials was undertaken on ClinicalTrials.gov on 13 May 2013. There were no restrictions on language or date of publication in the search of the electronic databases. Selection criteria Randomised or quasi‐randomised controlled trials with blind outcome assessment used or indicated, comparing topically‐applied fluoride varnish with placebo or no treatment in children up to 16 years during at least one year. The main outcome was caries increment measured by the change in decayed, missing and filled tooth surfaces in both permanent (D(M)FS) and primary (d(e/m)fs) teeth. Data collection and analysis At least two review authors assessed all search results, extracted data and undertook risk of bias independently. Study authors were contacted for additional information. The primary measure of effect was the prevented fraction, that is the difference in mean caries increments between the treatment and control groups expressed as a percentage of the mean increment in the control group. The caries increments nearest to three years were used from each included study. Random‐effects meta‐analyses were performed where data could be pooled. Potential sources of heterogeneity were examined in random‐effects meta‐regression analyses. Adverse effects information was collected from the included trials. Main results Twenty‐two trials with 12,455 participants randomised (9595 used in analyses) were included. For the 13 that contributed data for the permanent tooth surfaces meta‐analysis, the pooled D(M)FS prevented fraction estimate comparing fluoride varnish with placebo or no treatment was 43% (95% confidence interval (CI) 30% to 57%; P < 0.0001). There was substantial heterogeneity, confirmed statistically (P < 0.0001; I2 = 75%), however this body of evidence was assessed as of moderate quality. The pooled d(e/m)fs prevented fraction estimate was 37% (95% CI 24% to 51%; P < 0.0001) for the 10 trials that contributed data for the primary tooth surfaces meta‐analysis, also with some heterogeneity (P = 0.009; I2 = 59%). Once again this body of evidence was assessed as of moderate quality. No significant association between estimates of D(M)FS or d(e/m)fs prevented fractions and the pre‐specified factors of baseline caries severity, background exposure to fluorides, application features such as prior prophylaxis, concentration of fluoride, frequency of application were found. There was also no significant association between estimates of D(M)FS or d(e/m)fs prevented fractions and the post hoc factors: whether a placebo or no treatment control was used, length of follow‐up, or whether individual or cluster randomisation was used, in the meta‐regression models. A funnel plot of the trials in the main meta‐analyses indicated no clear relationship between prevented fraction and study precision. In both methods, power is limited when few trials are included. There was little information concerning possible adverse effects or acceptability of treatment. Authors' conclusions The conclusions of this updated review remain the same as those when it was first published. The review suggests a substantial caries‐inhibiting effect of fluoride varnish in both permanent and primary teeth, however the quality of the evidence was assessed as moderate, as it included mainly high risk of bias studies, with considerable heterogeneity.

31 March 2017 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
PJPatrice James
Patrice James
HWHelen V Worthington
Helen V Worthington
CPCarmel Parnell
Carmel Parnell
MHMairead Harding
Mairead Harding
TLThomas Lamont
Thomas Lamont
PRPhilip Riley
Philip Riley

20 January 2010 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
TWTanya Walsh
Tanya Walsh
HWHelen V Worthington
Helen V Worthington
AGAnne-Marie Glenny
Anne-Marie Glenny
PAPriscilla Appelbe
Priscilla Appelbe
VMValeria Cc Marinho
Valeria Cc Marinho
XSXin Shi
Xin Shi